50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional cure Data to be presented in late-breaker poster session at AASLD – The Liver Meeting® on Monday, November 18, 2024 WARMINSTER, Pa., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its exten ...

WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State ...

Financial Data and Key Metrics - The company ended Q3 2024 with approximately $131 million in cash, cash equivalents, and marketable securities, compared to $132 million as of December 31, 2023 [19] - Net proceeds from the issuance of common shares under the at-the-market offering program were approximately $44 million in the first half of 2024, offset by $54.5 million of cash used in operations [19] - The company expects its 2024 cash burn to range between $63 million and $67 million, with sufficient cash runway to fund operations into Q4 2026 [20] Business Line Data and Key Metrics - The IM-PROVE I clinical trial showed that 33% of patients in Cohort A1 achieved sustained surface antigen loss at 24 weeks post-treatment, with 67% of patients with baseline surface antigen <1,000 IU/mL maintaining surface antigen loss [9][10] - In the IM-PROVE II trial, 95% of patients achieved surface antigen levels <100 IU/mL prior to dosing with VTP-300 or placebo, with more patients maintaining thresholds <100 or <10 IU/mL versus placebo [12] - AB-101, the oral small molecule PD-L1 checkpoint inhibitor, demonstrated dose-dependent receptor occupancy in Phase Ia/Ib trials, with 7 out of 8 subjects in the 25-milligram cohort showing >70% receptor occupancy [16] Market Data and Key Metrics - Chronic HBV affects over 250 million people globally, with current treatments offering a functional cure rate of less than 10% [6][25] - The company is focused on developing a functional cure for HBV, aiming for a 20% functional cure rate, which would significantly reduce the risk of liver cirrhosis and hepatocellular carcinoma [7][25] Company Strategy and Industry Competition - The company is advancing imdusiran into a Phase IIb clinical trial as a cornerstone in a potential HBV functional cure treatment regimen, combining it with immune modulators like interferon and VTP-300 [13] - AB-101 is being developed to enhance HBV-specific immune responses in combination with imdusiran, with preliminary data from HBV patients expected in the first half of 2025 [14][17] - The company is involved in litigation with Moderna and Pfizer/BioNTech regarding LNP intellectual property, with trial dates set for September 2025 and December 2024, respectively [18] Management Commentary on Operating Environment and Future Outlook - The company remains committed to transforming the HBV treatment landscape and providing hope to millions of patients worldwide [49] - Management is optimistic about the upcoming data presentations at AASLD, including updates from the IM-PROVE I trial and preliminary data from the nivolumab arm of the IM-PROVE II trial [21] Other Important Information - The company has achieved all of its second-half milestones, including reporting multiple ascending dose data from healthy subjects in the AB-101-001 trial [21] Q&A Session Summary Question: Functional Cure Data Expectations - The company has not presented functional cure data for imdusiran yet but aims for a 20% functional cure rate as a meaningful benchmark [24][25] - All subjects in the IM-PROVE I study received at least 4 doses of imdusiran, with Cohort A1 continuing imdusiran during interferon treatment, while Cohort A2 received only interferon after the initial 4 doses [26] Question: Denominator for Functional Cure Calculation - The denominator for functional cure in Cohort A1 is 12 patients, with 33% achieving surface antigen loss [29] - Patients with baseline surface antigen <1,000 IU/mL showed a 67% surface antigen loss rate, aligning with industry trends [30] Question: AB-101 Data and Study Design - Preliminary data from AB-101 in HBV patients is expected in the first half of 2025, with biomarker collection ongoing to assess receptor occupancy and immune response [39][40] - The company plans to combine AB-101 with imdusiran as quickly as possible, following monotherapy evaluation [42] Question: IM-PROVE II Data at AASLD - The AASLD presentation will focus on Group C of the IM-PROVE II study, which includes low-dose nivolumab [43] Question: Litigation Update - The claim construction hearing for the Pfizer/BioNTech lawsuit is scheduled for December 18, 2024, with a trial date for the Moderna case set for September 24, 2025 [18][45] Question: Cash Runway and ATM Program - The company's cash runway into Q4 2026 does not include any expected proceeds from the ATM program [48]

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.10 per share when it actually produced a loss of $0.11, delivering a surprise of -10%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Arbutus, which belo ...

EXHIBIT 99.1 Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2 ...

WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Arbutus Biopharma (ABUS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Arbutus Biopharma is a member of our Medical group, which includes 1015 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Arbutus Biopharma is a member of our Medical group, which includes 1018 d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to | --- | --- | --- | --- | |------------------------------------------------------------------------------|------------------------------------------------------------- ...